Inicio › Leucemia linfocítica crónica › Illinois › Chicago
Ensayos clínicos de Leucemia linfocítica crónica en Chicago, IL
14 estudios para Leucemia linfocítica crónica buscan participantes en centros de Chicago y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ReclutandoFase 3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- y 1 más
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ReclutandoFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
ReclutandoFase 3
- Northwestern University, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
ReclutandoFase 1
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ReclutandoFase 3
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ReclutandoFase 3
- University of Chicago Medical Center, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutandoFase 1
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutandoFase 1
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
ReclutandoFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutandoFase 1
- The University of Chicago Medical Center, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Northwestern University, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
ReclutandoFase 1
- Northwestern Memorial Hospital, Chicago
Ensayos de Leucemia linfocítica crónica en otras ciudades
- Boston, MA31 estudios
- Columbus, OH29 estudios
- Durham, NC28 estudios
- Washington, DC22 estudios
- Seattle, WA22 estudios
- Rochester, MN20 estudios
- New York City, NY20 estudios
- Houston, TX18 estudios
- Baldwin Park, CA18 estudios
- Cincinnati, OH15 estudios
- Milwaukee, WI15 estudios
- Nashville, TN13 estudios
Otros estudios en Chicago
- Cáncer de seno59 estudios
- Cáncer de pulmón de células no pequeñas59 estudios
- Cáncer (todos los tipos)51 estudios
- Cáncer de próstata45 estudios
- Cáncer de pulmón43 estudios
- Cáncer metastásico42 estudios
- Obesidad40 estudios
- Cáncer de ovario36 estudios
- Cáncer del colon y del recto32 estudios
- Accidente cerebrovascular31 estudios
- Carcinoma de células escamosas de cabeza y cuello29 estudios
- Sobrepeso29 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.